What is Immunetics?
Immunetics specializes in a comprehensive array of biomedical products and services, encompassing antibodies, diagnostic tests, gene editing tools, and diverse assay technologies. Their offerings are tailored for clients within the immunology, molecular biology, and veterinary diagnostics sectors. The company is dedicated to supplying high-quality reagents and kits essential for both research and clinical applications. Through an established global distribution network, Immunetics effectively serves academic and commercial laboratories worldwide, positioning itself as a key player in the life sciences supply chain.
How much funding has Immunetics raised?
Immunetics has raised a total of $8.1M across 5 funding rounds:
Grant
$2.4M
Grant
$500K
Unspecified
$629K
Grant
$3.7M
Debt
$835K
Grant (2011): $2.4M with participation from National Institutes of Health
Grant (2011): $500K led by The Massachusetts Life Sciences Center
Unspecified (2012): $629K, investors not publicly disclosed
Grant (2012): $3.7M featuring National Institutes of Health
Debt (2014): $835K, investors not publicly disclosed
Key Investors in Immunetics
The Massachusetts Life Sciences Center
The Massachusetts Life Sciences Center (MLSC) is a hub for the global life sciences ecosystem, focusing on innovation through investments in science and business, and supporting workforce development and commercialization.
What's next for Immunetics?
The substantial capital raised, particularly the recent strategic investment, suggests Immunetics is poised for accelerated growth and market expansion. This financing is likely to fuel further research and development into advanced biomedical solutions, enhance their diagnostic capabilities, and broaden their global reach. The company's focus on high-quality reagents and assay technologies, coupled with its established distribution channels, positions it for continued leadership in supporting critical advancements in immunology and molecular biology research.
See full Immunetics company page
